This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
LIMK1 / LIM domain kinase 1 · IHC design guide
Design Immunohistochemistry for LIMK1
Plan LIMK1 staining in paraffin sections using tissue IHC patterns and the catalog antibody’s 1:50–1:200 dilution range (HPA tissue IHC; datasheet: A01323). Interpret cytoplasmic and nuclear signal with care because the antibody also targets LIMK2 (HPA tissue IHC; datasheet: A01323).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
LIMK1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Glandular and neuronal cells show cytoplasmic and nuclear staining (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Skeletal muscle |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01323) | |
| Caveat | The antibody also targets LIMK2; staining may not be LIMK1-specific (datasheet: A01323) | |
| Regulation | Brain-enhanced RNA expression (HPA tissue RNA) | |
| Isoform / epitope | 4 isoforms; isoform-specific epitope coverage is unknown (UniProt) |
Section 1
Recommended LIMK1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published LIMK1 IHC methods for prostate, osteosarcoma, and cervical cancer tissues (PMC7176864; PMC5768095; PMC8020211).
| Sample | Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A01323) |
| Fixation | Image fixative and duration unreported (datasheet A01323); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-LIMK1, 1:50-1:200 (datasheet A01323) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | LIMK1-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page retrieval rule); compare the published retrieval conditions during optimization.
Section 2
What Is the Expected LIMK1 Staining Pattern?
LIMK1 is predominantly cytoplasmic and can also appear in nuclei; it has no transmembrane segment (UniProt P53667). In paraffin sections, expect cytoplasmic and nuclear staining in many tissues, including strong staining in cerebral cortex neurons and several epithelial cell types (HPA tissue IHC). HPA rates its tissue IHC evidence Approved, with medium consistency between staining and RNA expression (HPA tissue IHC).
| Cerebral cortex neurons show clear cytoplasmic staining, with some nuclear staining. | This fits HPA's High neuronal staining in cerebral cortex and its cytoplasmic and nuclear tissue profile (HPA tissue IHC). UniProt describes LIMK1 as predominantly cytoplasmic (UniProt P53667). Compare signal with neighboring cells and the counterstain before scoring its distribution (general IHC practice). |
| Staining appears only at cell borders or in extracellular material, with no convincing intracellular signal. | A purely surface or extracellular pattern is unexpected for a protein without a transmembrane segment whose reported locations include cytoplasm and nucleus (UniProt P53667). Review morphology, nonspecific deposits and detection controls before calling it LIMK1 (general IHC practice). |
| Skeletal myocytes stain strongly while the expected positive cells on the same run do not. | HPA reports LIMK1 as Not detected in skeletal myocytes, while several epithelial populations and cerebral cortex neurons are High (HPA tissue IHC). Investigate possible cross-reactivity or endogenous chromogenic activity; this contrast alone cannot identify the cause (general IHC practice). |
| Color covers many tissue structures without clear cell boundaries or compartment enrichment. | Diffuse background cannot establish the cytoplasmic and nuclear pattern reported by HPA (HPA tissue IHC). Excess detection signal, incomplete blocking or inadequate washing can obscure cellular staining (general IHC practice). Judge a positive call only where morphology and cellular localization remain interpretable (general IHC practice). |
| No staining is visible in cerebral cortex neurons or another documented High population. | Absence of signal in an HPA High population makes the run difficult to interpret, but does not by itself prove LIMK1 is absent from the specimen (HPA tissue IHC; general IHC practice). Check that the positive control contains the intended cells, then review antibody and detection performance (general IHC practice). |
💡Expected LIMK1 appearanceCall a result positive when identifiable cerebral cortex neurons or an HPA High epithelial population show distinct cytoplasmic staining, with possible nuclear staining; a purely membranous deposit or uniform haze does not match the reported pattern (HPA tissue IHC; UniProt P53667; general IHC practice).
| Tissue and cell choice | HPA scores cerebral cortex neurons, cerebellar molecular-layer cells and several glandular or epithelial populations High, but skeletal myocytes Not detected (HPA tissue IHC). Select controls by cell type within the section, not by tissue name alone (general IHC practice). |
| Compartment and topology | UniProt places LIMK1 mainly in cytoplasm, also in nuclei, cytoskeleton and lamellipodia, and reports no transmembrane segment (UniProt P53667). HPA tissue IHC reports cytoplasmic and nuclear expression in most tissues (HPA tissue IHC). |
| Strength of tissue evidence | HPA labels the tissue IHC profile Approved and describes medium consistency with RNA data; external characterization supports the staining (HPA tissue IHC). HPA028516 and HPA073571 are IHC Approved, but neither is listed as IHC Enhanced in the supplied antibody record (HPA antibodies). |
| Isoforms and antibody epitope | UniProt lists four LIMK1 isoforms (UniProt P53667). The supplied record gives no epitope for the catalog antibody, so its coverage of individual isoforms cannot be inferred. Treat differences between specimens as observations until antibody recognition is established (general IHC practice). |
| IF/ICC cross-check | For IF/ICC interpretation, HPA reports supported cytosol and nuclear-speckle localization, with images from A-431, U-251MG and U2OS (HPA subcellular). Nuclear speckles observed by IF/ICC should not be required to call a chromogenic tissue IHC section positive (HPA subcellular; HPA tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| Positive-control cerebral cortex neurons are blank. | The control may lack identifiable neurons, or staining and detection may have failed; HPA scores these cells High (HPA tissue IHC; general IHC practice). | Confirm the intended cells on the counterstained section, then check antibody application, detection reagents and a documented positive control (general IHC practice). Optimize retrieval empirically if the general workflow requires it; target-specific fixation sensitivity is unreported in the supplied sources. |
| Signal is confined to cell borders or extracellular deposits. | This conflicts with the reported intracellular locations and lack of a transmembrane segment (UniProt P53667). Deposits or nonspecific staining are possible explanations (general IHC practice). | Inspect the unstained morphology and a detection control; assess whether any reproducible cytoplasmic or nuclear staining remains in an HPA High cell population (HPA tissue IHC; general IHC practice). |
| Skeletal myocytes are strongly stained. | HPA reports skeletal myocytes as Not detected, so strong staining there needs scrutiny; the result alone cannot distinguish cross-reactivity from endogenous chromogenic activity (HPA tissue IHC; general IHC practice). | Compare with an HPA High control and a primary-antibody omission control. Review endogenous activity blocking and deposits according to the detection chemistry (HPA tissue IHC; general IHC practice). |
| The whole section shows diffuse color. | Background may mask the cytoplasmic and nuclear pattern reported for tissue IHC (HPA tissue IHC). Excess detection signal or insufficient washing can produce diffuse color (general IHC practice). | Compare with the omission control; review blocking, washes and detection development, then score only cells whose boundaries and compartments can be resolved (general IHC practice). |
| Only nuclei stain, with no cytoplasmic signal in a documented positive population. | LIMK1 can be nuclear, but UniProt describes it as predominantly cytoplasmic and HPA reports both compartments in most tissues (UniProt P53667; HPA tissue IHC). An exclusively nuclear result needs verification. | Recheck cellular morphology and compare another HPA High cell population. Confirm that cytoplasmic signal is distinguishable from background before interpreting the nuclear-only pattern (HPA tissue IHC; general IHC practice). |
| IF/ICC shows nuclear speckles that are unclear in chromogenic IHC. | HPA supports nuclear speckles and cytosol in ICC-IF, while its tissue IHC description is cytoplasmic and nuclear without a speckle requirement (HPA subcellular; HPA tissue IHC). | Interpret the paraffin-section result against the tissue IHC profile and its cell-level controls. Use the IF/ICC observation as localization context rather than requiring visible speckles in the chromogenic section (HPA subcellular; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing LIMK1 staining
A01323 · IHCImmunohistochemistry (IHC) analyzes of LIMK1/2 (D402) pAb in paraffin-embedded human breast carcinoma tissue at 1:100.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000106683-LIMK1/tissue/cerebral+cortex#imid_8029839
HPA · StomachHuman Protein Atlas IHC, Stomach. Source: https://www.proteinatlas.org/ENSG00000106683-LIMK1/tissue/stomach+1#imid_8029723
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000106683-LIMK1/tissue/colon#imid_8029765
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000106683-LIMK1/tissue/liver#imid_8029750
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA028516; green = LIMK1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA028516; green = LIMK1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for LIMK1 IHC & IF
🧪Run cerebral cortex first and score neuronal cells for LIMK1 staining (HPA: High in cerebral cortex neuronal cells; UniProt P53667: highest adult brain expression in cerebral cortex). Use skeletal muscle myocytes as the negative tissue (HPA: Not detected); on the cortex slide, non-neuronal cells are candidate internal negatives only if independently verified as LIMK1-negative, in which case they should remain at background.
Positive control tissue: Appendix (Glandular cells, HPA High)
Negative control tissue: Skeletal muscle (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show LIMK1 in A-431, U-251MG, U2OS, with annotated localisation: Nuclear speckles (supported), Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species and immunoglobulin class; and LIMK1-knockout tissue as a biological specificity control (standard IHC practice). For cortex, quench endogenous peroxidase before chromogenic detection and distinguish neuronal pigment from chromogen; for IF, assess tissue autofluorescence with an unstained section (standard IHC/IF practice).
⚠️Feasibility: A LIMK1-specific fixation window and antigen-retrieval requirement are unreported in the supplied evidence; optimize retrieval empirically (supplied target/application evidence). The selected A01323 paraffin-section caption does not report a fixative and describes LIMK1/2 staining, so it does not establish fixation or LIMK1-only specificity (selected-SKU tissue-IHC caption). The evidence does not establish whether frozen sections or IF are easier; cortical lipofuscin can complicate fluorescence interpretation (standard IF practice), while ICC-IF images support cytosolic and nuclear-speckle localization (HPA subcellular). The selected A01323 tissue-IHC caption documents paraffin sections, but does not specify the fixative (selected-SKU IHC image A01323).
HPA tissue IHC evidence for LIMK1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. External characterization data supports antibody staining.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in molecular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skeletal muscle | Myocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced LIMK1 IHC Tips
Troubleshoot LIMK1 staining in paraffin sections by checking retrieval, compartment pattern, antibody specificity, and cell-level scoring before interpreting chromogenic signal.
What retrieval should I start with for LIMK1 in paraffin sections?
Start with Tris-EDTA pH 9.0 heat-induced epitope retrieval at 95–98 °C for 20 min (page retrieval rule: nuclear antigen). Cool sections in retrieval buffer before washing, and process comparison slides together so temperature and timing remain comparable (standard IHC practice). If staining is weak, vary retrieval time on matched sections while keeping antibody concentration and detection conditions fixed (standard IHC practice). Evaluate both cytoplasmic and nuclear signal, since LIMK1 is predominantly cytoplasmic but also occurs in the nucleus (UniProt P53667 localisation). The A01323 caption documents staining in paraffin-embedded breast carcinoma at 1:100 but does not report its retrieval conditions (A01323 tissue-IHC caption).
Could fixation explain weak or uneven LIMK1 staining?
Target-specific fixation sensitivity is unknown because the supplied LIMK1 tissue-IHC caption does not state a fixative (A01323 tissue-IHC caption). Record the fixative, fixation duration, section thickness, and storage history for each block before comparing staining intensity (standard IHC practice). For a suspected processing effect, stain matched sections from blocks with documented handling in the same run, using identical retrieval and detection conditions (standard IHC practice). Compare intact central tissue with section edges, folds, and poorly preserved areas before changing antibody concentration (standard IHC practice). Do not assign a particular fixation effect to LIMK1 from its tissue distribution or molecular features alone (HPA tissue IHC; UniProt P53667 record).
Where should convincing LIMK1 chromogenic staining appear?
Expect predominantly cytoplasmic staining, with possible nuclear signal, because those are recorded LIMK1 locations (UniProt P53667 localisation). Cytoplasmic and nuclear staining across many tissues is also reported by tissue IHC, although its antibody staining has medium consistency with RNA expression (HPA tissue IHC). Score the two compartments separately and identify the stained cell type on the counterstained section (standard IHC practice). A narrow peripheral signal can be biologically plausible because LIMK1 can localize to lamellipodia under specified partner-dependent conditions, but routine chromogenic sections may not resolve that structure (UniProt P53667 localisation; standard IHC practice). Recheck an exclusively extracellular pattern against tissue morphology and controls (UniProt P53667 topology; standard IHC practice).
How do isoforms and epitope location affect an IHC result?
LIMK1 has 4 recorded isoforms and LIM, PDZ, and kinase domains, so identify the catalog antibody's stated immunogen before assuming every isoform is detected (UniProt P53667 domains and isoforms; standard IHC practice). The supplied A01323 caption calls its reagent a LIMK1/2 antibody, making LIMK1-specific attribution uncertain from that image alone (A01323 tissue-IHC caption). If the epitope sequence is available, compare it with the isoforms and any stated LIMK2 cross-reactivity (standard IHC practice). Recorded LIMK1 phosphorylation sites include residues 210, 229, and 298, but their effect on this antibody's staining is unreported (UniProt P53667 modified residues; A01323 tissue-IHC caption). Use an independently characterized reagent when isoform or paralog assignment matters (standard IHC practice).
How can IF help assess a questionable LIMK1 IHC pattern?
Use IF/ICC as a separate comparison of compartment pattern, since supported LIMK1 locations include cytosol and nuclear speckles (HPA subcellular). Multiplex LIMK1 with a validated marker for the cell population being assessed, and include single-stain controls to check channel bleed-through (standard IF practice). Choose a fluorophore whose signal is distinguishable from autofluorescence in the actual tissue, checking an unstained section before interpreting weak signal (standard IF practice). LIMK1 has no transmembrane segment, so permeabilise sufficiently to access intracellular epitopes while preserving cell structure (UniProt P53667 topology; standard IF practice). The paraffin-section A01323 image does not establish IF/ICC fixation or permeabilisation conditions (A01323 tissue-IHC caption).
How should I reduce diffuse or misleading LIMK1 chromogenic background?
Check a no-primary control alongside the test section to identify signal arising from detection reagents or endogenous tissue activity (standard IHC practice). Block endogenous peroxidase before an enzyme-based chromogenic reaction, then compare DAB development times on matched sections (standard IHC practice). If diffuse staining persists, optimize blocking, antibody concentration, wash stringency, and development time one variable at a time (standard IHC practice). The A01323 image reports 1:100 in paraffin-embedded breast carcinoma; treat that as its image condition rather than a universal working dilution (A01323 tissue-IHC caption). Retain interpretable cytoplasmic and nuclear morphology while evaluating any reduction in background (UniProt P53667 localisation; standard IHC practice).
What scoring method captures LIMK1 staining without obscuring its localisation? ⚠ ANSWER MARKED FOR VERIFICATION
Choose a defined cell population and score cytoplasmic and nuclear staining separately, reflecting the reported LIMK1 distribution (UniProt P53667 localisation; HPA tissue IHC). For each compartment, record the percentage of positive cells and an intensity category, then calculate an H-score using the same thresholds across slides (standard IHC practice). Normalize counts to the number of evaluable cells, or report positive-cell density per mm² of viable annotated tissue when cell counting is impractical (standard IHC practice). Exclude folds, necrosis, and section edges using prespecified rules, and keep acquisition and DAB analysis settings fixed (standard IHC practice). Compare like cell types across samples because LIMK1 staining varies among reported tissue cell populations (HPA tissue IHC).
When is a LIMK1-positive result likely to be artefactual?
A credible result follows cell morphology and a plausible cytoplasmic or nuclear distribution, rather than staining only acellular material (UniProt P53667 localisation; standard IHC practice). Compare the stained cells with an expected reference population: HPA reports high staining in cerebral cortex neuronal cells and no detection in skeletal muscle myocytes (HPA tissue IHC). Edge-only staining, necrotic patches, and signal reproduced in a no-primary control warrant investigation before assigning positivity (standard IHC practice). Check endogenous peroxidase blocking if DAB appears in the control, and review the counterstain to locate the signal within viable cells (standard IHC practice). Because the A01323 caption identifies a LIMK1/2 antibody, its positive image alone cannot establish LIMK1-specific staining (A01323 tissue-IHC caption).
Boster reagents
Best LIMK1 / LIM domain kinase 1 IHC Antibodies
A01323 has a human paraffin-section IHC image (A01323 image caption). The catalog lists human, mouse and rat reactivity (A01323 reactivity); it provides no IF image (A01323 IF image list).
Real IHC data
Anti-LIMK1/2 (D402) Antibody
Cat # A01323
A01323 is listed for IHC and has an image from paraffin-embedded human breast carcinoma at 1:100 (A01323 applications; A01323 image caption). Its listed reactivity is human, mouse and rat; the payload provides no IF image (A01323 reactivity; A01323 IF image list).
Which to pick: For tissue IHC, choose A01323, a rabbit polyclonal antibody with an IHC application and a human paraffin-section image; the caption does not report the fixative (A01323 host; A01323 image caption; A01323 applications). For IF/ICC, the payload supports no SKU: A01323 has no listed IF/ICC application or IF image (A01323 applications; A01323 IF image list). For cross-species work, A01323 lists human, mouse and rat reactivity, while its IHC image documents human tissue only (A01323 reactivity; A01323 image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P53667 (LIMK1_HUMAN, LIM domain kinase 1).
- Human Protein Atlas. LIMK1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. LIMK1 subcellular location (ICC-IF): Localized to the nuclear speckles and cytosol..
- Human Protein Atlas. LIMK1 antibody validation summary (2 antibodies).
- Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence. Journal of cellular and molecular medicine 2020 — PMC7176864.
- LIMK1 Interacts with STK25 to Regulate EMT and Promote the Proliferation and Metastasis of Colorectal Cancer. Journal of oncology 2022 — PMC8901301.
- LIM kinase 1 serves an important role in the multidrug resistance of osteosarcoma cells. Oncology letters 2018 — PMC5768095.
- FOXD3‑AS1/miR‑128‑3p/LIMK1 axis regulates cervical cancer progression. Oncology reports 2021 — PMC8020211.
- PubMed PMID:8183554 — UniProt-cited evidence.
- PubMed PMID:8689688 — UniProt-cited evidence.
- PubMed PMID:8812460 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for LIMK1 (LIM domain kinase 1). Expected localisation Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: A01323 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative Skeletal muscle. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A01323); 2. Fixation: Image fixative and duration unreported (datasheet A01323); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-LIMK1, 1:50-1:200 (datasheet A01323); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01323); Caveat: The antibody also targets LIMK2; staining may not be LIMK1-specific (datasheet: A01323); Isoform / epitope: 4 isoforms; isoform-specific epitope coverage is unknown (UniProt); Regulation: Brain-enhanced RNA expression (HPA tissue RNA). Evidence: UniProt P53667, HPA tissue IHC · Approved, HPA ICC-IF · nuclear speckles and cytosol., Datasheet A01323, PMC7176864, PMC5768095. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/LIMK1/immunohistochemistry-ihc-guide.